Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EBT (2018 - 2025)

Serina Therapeutics' EBT history spans 8 years, with the latest figure at -$6.4 million for Q3 2025.

  • For Q3 2025, EBT fell 20.08% year-over-year to -$6.4 million; the TTM value through Sep 2025 reached -$23.4 million, down 435.75%, while the annual FY2024 figure was -$17.6 million, 376.65% down from the prior year.
  • EBT for Q3 2025 was -$6.4 million at Serina Therapeutics, down from -$5.6 million in the prior quarter.
  • Across five years, EBT topped out at $7.6 million in Q4 2023 and bottomed at -$6.4 million in Q3 2025.
  • The 5-year median for EBT is -$2.5 million (2024), against an average of -$2.7 million.
  • The largest annual shift saw EBT skyrocketed 376.85% in 2023 before it plummeted 296.3% in 2024.
  • A 5-year view of EBT shows it stood at -$2.3 million in 2021, then decreased by 22.02% to -$2.8 million in 2022, then surged by 376.85% to $7.6 million in 2023, then plummeted by 172.84% to -$5.6 million in 2024, then decreased by 14.95% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SER's EBT are -$6.4 million (Q3 2025), -$5.6 million (Q2 2025), and -$5.9 million (Q1 2025).